APIs and Excipients

August 01, 2019

Biopharma industry faces production challenges as gene therapies move from clinical to commercialization.

August 01, 2019

Mass-produce cell and gene therapies presents the biopharma industry with a unique set of challenges.

July 16, 2019

An agreement with Sanofi gives Catalent access to commercial spray drying facility in Haverhill, UK.

July 02, 2019

Nanotechnology is enabling enhanced bioavailability, improved stability, and targeted delivery of challenging APIs.

June 24, 2019

The biosimilar, Kanjinti, is approved for all indications of Herceptin, which includes treating breast, gastric, and gastroesophogeal cancers.

June 19, 2019

New CDMO facility supports early-stage API manufacturing and scale up.

June 17, 2019

Two additional production lines expand Lonza’s HPAPI capacity at Visp, Switzerland facility.

June 17, 2019

Pfizer’s acquisition of Array BioPharma expands the company’s pipeline of investigational cancer therapies.

June 02, 2019

Excipients and new processing techniques can make a real difference in the development of highly potent therapies.

May 24, 2019

The agency has approved Zolgensma (onasemnogene abeparvovec-xioi), the first gene therapy to treat pediatric spinal muscular atrophy.